Moderna stock ( NASDAQ:MRNA ) were priced at $130.72 at the close of the most recent trading session, representing an increase of 8.3%. The rise was accompanied by a significant increase in volume, with a greater number of shares being traded than is typical for a given session. This is in contrast to the stock’s decline of 8.1% over the course of the last four weeks.
As a result of the management of Moderna’s announcement that the pharmaceutical giant Merck had exercised an option to jointly develop and commercialize Moderna’s personalized cancer vaccine (PCV) mRNA-4157/V940, share prices for Moderna likely increased. This was done in accordance with an existing collaboration agreement between the two companies. Because Merck is exercising this option, Moderna will receive a payment from Merck in the amount of $250 million, as stipulated in the agreement.
Moderna Stock Forecasted Price
In the forthcoming report, this biotechnology firm is anticipated to announce quarterly earnings of $5.20 per share, which represents a change year-over-year of -32.5%. It is anticipated that revenues will total $4.92 billion, representing a 1% decrease from the same quarter a year earlier.
Earnings and revenue growth expectations certainly provide a good sense of the potential strength of stock; however, empirical research demonstrates that trends in earnings estimate revisions are strongly correlated with near-term stock price movements. This suggests that earnings estimate revisions are a better indicator of a stock’s potential strength.
Over the course of the past 30 days, the consensus earnings per share estimate for Moderna&...
Click here to read the full article on PressReach.com .Subscribe to the PressReach RSS feeds:
- Featured News RSS feed
- Investing News RSS feed
- Daily Press Releases RSS feed
- Trading Tips RSS feed
- Investing Videos RSS feed
Follow PressReach on Twitter
Follow PressReach on TikTok
Follow PressReach on Instagram
Subscribe to us on Youtube